This structure isn't a weakness, it's a smart, capital-efficient move. The share charge is a normal way to finance things, and it doesn't take away Willowglen's profits from Elixir II. Instead of worrying about temporary issues, shareholders should look at whether the asset itself makes more money than it costs to finance. If it does, this deal boosts long-term value without diluting shares or draining cash.